Papaxoinis, George <br/><br/>
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.  [electronic resource] 

 -  Medical oncology (Northwood, London, England)  May 2018 
 - 101 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1559-131X 
<br/><br/><label>Standard No.: </label>10.1007/s12032-018-1160-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Capecitabine--administration & dosage<br/>Colorectal Neoplasms--drug therapy<br/>Female<br/>Genotype<br/>Humans<br/>Male<br/>Middle Aged<br/>Mutation<br/>Neoplasm Staging<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Panitumumab<br/>Retrospective Studies<br/>Survival Analysis<br/>Treatment Outcome<br/>Tumor Suppressor Protein p53--genetics